- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Diphosphate.
Displaying page 1 of 2.
EudraCT Number: 2007-003114-34 | Sponsor Protocol Number: CUR001 | Start Date*: 2007-11-29 |
Sponsor Name:Department of Nephrology and Renal Transplantation, University Hospitals Leuven | ||
Full Title: The impact of oral curcumin (Curcuma longa) on mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients: exploratory investigation of the role of intestinal uridine-di... | ||
Medical condition: Stable renal allograft recipients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-000945-20 | Sponsor Protocol Number: vitk2006 | Start Date*: 2006-08-22 | |||||||||||
Sponsor Name:Barts and the London NHS Trust | |||||||||||||
Full Title: To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004272-11 | Sponsor Protocol Number: 2B | Start Date*: 2011-11-30 |
Sponsor Name:Erasmus MC | ||
Full Title: The BOKITO-2B Study: Tenofovir DF Bone and Kidney Toxicity. Incidence and reversibility in HBV-monoinfected patients. | ||
Medical condition: Chronic hepatitis B | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004357-13 | Sponsor Protocol Number: CTH201401 | Start Date*: 2015-03-18 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Coagaulation in patients with atrial fibrillation: The effect of dabigatran | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004266-26 | Sponsor Protocol Number: RIVAROXACS2002 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in Addition to Either Clopidogrel or ... | |||||||||||||
Medical condition: Acute Coronary Syndrome (ACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) IT (Completed) BG (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003140-71 | Sponsor Protocol Number: RMFPC-22 | Start Date*: 2020-08-25 | |||||||||||
Sponsor Name:Rockwell Medical, Inc. | |||||||||||||
Full Title: Hemoglobin maintenance in pediatric ESRD patients by ferric pyrophosphate citrate (FPC) | |||||||||||||
Medical condition: Iron deficiency anaemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000813-39 | Sponsor Protocol Number: H7T-MC-TABL | Start Date*: 2006-11-27 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Prasugrel in comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE) - TIMI 44 | |||||||||||||
Medical condition: subjects undergoing elective cardiac catheterization with planned percutaneous coronary intervention (PCI) with coronary stenting. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000574-40 | Sponsor Protocol Number: PSP-CoQ10 | Start Date*: 2006-04-24 |
Sponsor Name:Kompetenznetz Parkinson e.V. | ||
Full Title: Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® | ||
Medical condition: PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 10... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-007934-21 | Sponsor Protocol Number: MI2-INCA-2007 | Start Date*: 2007-06-27 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: Intracellular concentration of Antiretrovirals)INCA STADY | |||||||||||||
Medical condition: HIV -immunodefic syndrome- | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003745-16 | Sponsor Protocol Number: 3639a | Start Date*: 2008-10-28 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust | ||
Full Title: Assessment of platelet-dependent thrombosis by an ex vivo arterial injury model: a placebo controlled trial of Clopidogrel as antiplatelet therapy in patients with type 2 diabetes mellitus and coro... | ||
Medical condition: Type 2 Diabetes Mellitus and Coronary Artery Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002618-37 | Sponsor Protocol Number: H7T-MC-TABN | Start Date*: 2006-12-28 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Cross-Over Study Comparing the Pharmacodynamic Response in Subjects with Acute Coronary Syndrome Receiving 14 Days 10-mg Maintenance Dose Prasugrel (LY640315) versus 14 ... | |||||||||||||
Medical condition: subjects with acute coronary syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001371-69 | Sponsor Protocol Number: EVITAs | Start Date*: 2016-09-30 |
Sponsor Name:Fundació Lluita contra la SIDA | ||
Full Title: Tenofovir DP concentrations in seminal cells and semen quality in HIV-1 infected patients receiving a TAF containing regimen | ||
Medical condition: HIV-1 positive patients | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001774-88 | Sponsor Protocol Number: TAR-ORI-SD001 | Start Date*: 2007-11-15 | |||||||||||
Sponsor Name:Targanta Therapeutics Corporation | |||||||||||||
Full Title: Nuvocid™ (oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI) | |||||||||||||
Medical condition: Complicated skin and skin structure infections (cSSSI). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021424-94 | Sponsor Protocol Number: TMC-ORI-10-01 | Start Date*: 2012-03-16 | |||||||||||||||||||||||||||||||
Sponsor Name:The Medicines Company | |||||||||||||||||||||||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin versus IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin... | |||||||||||||||||||||||||||||||||
Medical condition: Treatment of Patients with acute bacterial skin and skin structure infections | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) PL (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003984-37 | Sponsor Protocol Number: CMX001-211 | Start Date*: 2018-07-30 | |||||||||||
Sponsor Name:Chimerix, Inc | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients with Adenovirus Viremia | |||||||||||||
Medical condition: Treatment of adenovirus infections in adult allogeneic hematopoietic cell transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003633-32 | Sponsor Protocol Number: CERL080A2419 | Start Date*: 2006-11-13 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, multi-center, parallel-group, open-label study to evaluate the therapeutical benefit of an initially intensified dosing regimen of Myfortic® vs. a standard dosing regimen of Myfortic... | ||
Medical condition: Prophylaxis of rejection in recipients of first or second cadaveric, living unrelated or living related kidney transplants | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) AT (Completed) IT (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002359-39 | Sponsor Protocol Number: 213406 | Start Date*: 2020-09-18 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||||||||||||||||||
Full Title: A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS | ||||||||||||||||||
Medical condition: Recurrent or refractory solid tumour | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021720-10 | Sponsor Protocol Number: TMC-ORI-10-02 | Start Date*: 2012-03-16 | |||||||||||||||||||||||||||||||
Sponsor Name:The Medicines Company | |||||||||||||||||||||||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin versus IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin... | |||||||||||||||||||||||||||||||||
Medical condition: Treatment of Patients with acute bacterial skin and skin structure infections | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002830-19 | Sponsor Protocol Number: GS-US-292-0117 | Start Date*: 2013-11-27 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alaf... | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003176-16 | Sponsor Protocol Number: ADP-0055-003/GOG-3084 | Start Date*: 2023-07-03 |
Sponsor Name:Adaptimmune LLC | ||
Full Title: A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084) | ||
Medical condition: Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Trial now transitioned) ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
